scholarly journals Interaction between Posaconazole and Caspofungin in Concomitant Treatment of Mice with Systemic Aspergillus Infection

2006 ◽  
Vol 50 (7) ◽  
pp. 2587-2590 ◽  
Author(s):  
Anthony Cacciapuoti ◽  
Judith Halpern ◽  
Cara Mendrick ◽  
Christine Norris ◽  
Reena Patel ◽  
...  

ABSTRACT The interaction of posaconazole and caspofungin was evaluated in concomitant treatment of Aspergillus fumigatus (two strains) or A. flavus (one strain) systemic infections in immunocompetent mice. Survival curves for mice treated with the combinations were compared statistically with those for mice treated with the component monotherapies. No antagonism was observed.

2005 ◽  
Vol 49 (2) ◽  
pp. 638-642 ◽  
Author(s):  
Anthony Cacciapuoti ◽  
Maya Gurnani ◽  
Judith Halpern ◽  
Christine Norris ◽  
Reena Patel ◽  
...  

ABSTRACT The interaction of posaconazole and amphotericin B was evaluated in concomitant treatment of Candida albicans systemic infections in immunocompetent mice by using four strains of C. albicans with different susceptibilities to fluconazole. Posaconazole and amphotericin B were each tested at four dose levels alone and in all possible combinations against each C. albicans strain. Survival curves of mice treated with combinations of posaconazole and amphotericin B were statistically compared with those of mice treated with the component monotherapies. Of the 64 total combinations evaluated against the C. albicans strains (16 combinations per strain), 20.3% were more effective in prolonging mouse survival than both of the monotherapies, 45.3% were more effective than one of the monotherapies, and 32.8% were similar to both monotherapies. No evidence of antagonism was observed between posaconazole and amphotericin B in this mouse model, consistent with in vitro results against the same strains.


2017 ◽  
Vol 56 (6) ◽  
pp. 703-710
Author(s):  
Michaela Lackner ◽  
Günter Rambach ◽  
Emina Jukic ◽  
Bettina Sartori ◽  
Josef Fritz ◽  
...  

Abstract No data are available on the in vivo impact of infections with in vitro azole-resistant Aspergillus fumigatus in immunocompetent hosts. Here, the aim was to investigate fungal fitness and treatment response in immunocompetent mice infected with A. fumigatus (parental strain [ps]) and isogenic mutants carrying either the mutation M220K or G54W (cyp51A). The efficacy of itraconazole (ITC) and posaconazole (PSC) was investigated in mice, intravenously challenged either with a single or a combination of ps and mutants (6 × 105 conidia/mouse). Organ fungal burden and clinical parameters were measured. In coinfection models, no fitness advantage was observed for the ps strain when compared to the mutants (M220K and G54W) independent of the presence or absence of azole-treatment. For G54W, M220K, and the ps, no statistically significant difference in ITC and PSC treatment was observed in respect to fungal kidney burden. However, clinical parameters suggest that in particular the azole-resistant strain carrying the mutation G54W caused a more severe disease than the ps strain. Mice infected with G54W showed a significant decline in body weight and lymphocyte counts, while spleen/body weight ratio and granulocyte counts were increased. In immunocompetent mice, in vitro azole-resistance did not translate into therapeutic failure by either ITC or PSC; the immune system appears to play the key role in clearing the infection.


1999 ◽  
Vol 43 (3) ◽  
pp. 589-591 ◽  
Author(s):  
M. Lozano-Chiu ◽  
S. Arikan ◽  
V. L. Paetznick ◽  
E. J. Anaissie ◽  
D. Loebenberg ◽  
...  

ABSTRACT Doses of 10 to 100 mg of the azole antifungal agent SCH 56592/kg of body weight/day were studied in immunocompetent mice as therapy for systemic infection by Fusarium solani. Treatment was begun 1 h after intravenous infection and continued daily for 4 or 13 doses. Prolongation of survival and organ clearance were dependent on both the dose and the duration of SCH 56592 therapy, with the best results seen at 50 and 100 mg/kg/day. The results at the highest doses of SCH 56592 used (50 or 100 mg/kg/day) were comparable to those obtained with amphotericin B at 1 mg/kg/day. SCH 56592 has potential for therapy of systemic infections caused byF. solani.


1997 ◽  
Vol 41 (10) ◽  
pp. 2238-2243 ◽  
Author(s):  
T L Wallace ◽  
V Paetznick ◽  
P A Cossum ◽  
G Lopez-Berestein ◽  
J H Rex ◽  
...  

The purpose of this study was to examine the activity of liposomal nystatin against a disseminated Aspergillus fumigatus infection in neutropenic mice. Mice were made neutropenic with 5-fluorouracil and were administered the antifungal drug intravenously for 5 consecutive days beginning 24 h following infection. Liposomal nystatin, at doses as low as 2 mg/kg of body weight/day, protected neutropenic mice against Aspergillus-induced death in a statistically significant manner at the 50-day time point compared to either the no-treatment, the saline, or the empty-liposome group. This protection was approximately the same as that for free nystatin, a positive control. Histopathological results showed that liposomal nystatin cleared the lungs, spleen, pancreas, kidney, and liver of Aspergillus and that there was no organ damage at the day 5 time point, which was after only three doses of liposomal nystatin. Based on these results in mice, it is probable that liposomal nystatin will be effective against Aspergillus infection in humans.


2019 ◽  
Vol 14 (17) ◽  
pp. 1511-1525 ◽  
Author(s):  
Nathália LSO Malacco ◽  
Jéssica AM Souza ◽  
Aline C Mendes ◽  
Milene A Rachid ◽  
Lucas R Kraemer ◽  
...  

Aim: Characterize the course of acute Aspergillus fumigatus lung infection in immunocompetent mice, investigating the immunological, pathological and tissue functional modifications. Materials & methods: C57BL/6 mice were intranasally infected with A. fumigatus conidia and euthanized to access inflammatory parameters. Results: Mice infected with A. fumigatus showed an inoculum-dependent lethality and body weight loss. An intense proinflammatory cytokine release, neutrophil infiltrate and pulmonary dysfunction was also observed in the early phase of infection. In the late phase of infection, proresolving mediators release, apoptosis and efferocytosis increased and lung tissue architecture is restored. Conclusion: Our study characterized an immunocompetent model of acute pulmonary Aspergillus infection in mice and opened an array of possibilities for investigations on interactions of A. fumigatus with host-immune system.


2001 ◽  
Vol 69 (3) ◽  
pp. 1554-1560 ◽  
Author(s):  
Joan K. Brieland ◽  
Craig Jackson ◽  
Fred Menzel ◽  
David Loebenberg ◽  
Anthony Cacciapuoti ◽  
...  

ABSTRACT Cytokine networking in the lung in response to inhaledAspergillus fumigatus was assessed using a murine model of primary pulmonary aspergillosis in immunocompetent Crl:CF-1 mice. Inhalation of virulent A. fumigatus (6 × 106 CFU) resulted in the induction of interleukin 18 (IL-18), tumor necrosis factor alpha (TNF-α), IL-12, and gamma interferon (IFN-γ) protein in bronchoalveolar lavage fluid and/or lung tissue. Induction of immunoreactive IL-18 preceded induction of TNF-α protein, which preceded induction of immunoreactive IL-12 and IFN-γ. Real-time reverse transcriptase (RT) PCR analysis of infected lung tissue demonstrated that induction of IL-18 protein also preceded induction of pulmonary TNF-α, IL-12, and IFN-γ mRNAs. Mice were subsequently treated with cytokine-specific neutralizing monoclonal antibodies (MAbs) to the IL-18 receptor (anti-IL-18R MAb), TNF-α (anti-TNF-α MAb), IL-12 (anti-IL-12 MAb), and/or IFN-γ (anti-IFN-γ MAb), and effects on intrapulmonary cytokine activity and growth of A. fumigatuswere assessed in infected lung homogenates. Simultaneous neutralization of IL-12 and IL-18 resulted in decreased levels of immunoreactive TNF-α, while neutralization of IL-18, TNF-α, or IL-12 alone or of IL-18 and IL-12 together resulted in decreased levels of immunoreactive IFN-γ. Simultaneous neutralization of IL-12 and IL-18 or neutralization of TNF-α alone or in combination with IL-12, IL-18, or IFN-γ also resulted in a significant increase inA. fumigatus CFU in lung tissue. Taken together, these results demonstrate that endogenous IL-18, IL-12, and TNF-α, through their modulatory effects on both intrapulmonary cytokine activity and growth of A. fumigatus, play key roles in host defense against primary pulmonary aspergillosis.


2007 ◽  
pp. 255-259
Author(s):  
Ivana Mirkov ◽  
Milena Kataranovski ◽  
Marina Sokovic ◽  
Jasmina Glamoclija ◽  
Lidija Zolotarevski ◽  
...  

In this study systemic response to intravenous administration of Aspergillus fumigatus conidia was investigated. The intensity of response was evaluated by a survival rate and by histopathological tissue analysis. Administration of all doses (106 - 5x107) of Aspergillus fumigatus conidia caused mortality, but the highest mortality and the shorter time of survival were noted at higher doses applied. At the highest applied dose, the presence of spores and hyphae was noted in lungs and kidneys. Histological analysis revealed the presence of intense inflammatory reaction in lungs, kidneys and spleen. Functional and histological changes observed provide means to study both mechanisms and drug interventions in systemic Aspergillus infection.


Mycoses ◽  
2020 ◽  
Vol 63 (10) ◽  
pp. 1083-1093
Author(s):  
Shiang‐Fen Huang ◽  
Shi‐Yi Li ◽  
Yu‐Jiun Chan ◽  
Yu‐Chi Huang ◽  
Ying‐Ying Yang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document